A Study of Enasidenib in People With T-Cell Lymphoma
Plain-language summary
This trial is testing Enasidenib for patients with angioimmunoblastic T-cell lymphoma (AITL) or other nodal T-follicular helper (TFH) lymphomas whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 8 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Enasidenib (DRUG): Enasidenib 100 mg daily on 28-day cycles. | Rituximab (DRUG): IV rituximab 375 mg/m² weekly for the first month, and monthly thereafter on 28-day cycles, for a total of four months of rituximab.
Enasidenib, Rituximab
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details